Keywords: Novo Nordisk, BLA, USA, Congenital factro XIII, FXIII, Bleeding disorder

Novo Nordisk files BLA for first recombinant treatment for FXIII in USA

Article | 24 February 2011

Print This

The US unit of Danish insulin giant Novo Nordisk (NVO: N) has submitted a Biologic License Application (BLA) to the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in